Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A2102 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
SHR-A2102 + bevacizumab is an investigational combination therapy involving two agents: **SHR-A2102**, a small-molecule oral tyrosine kinase inhibitor, and **bevacizumab**, a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). SHR-A2102 is under development for use in advanced solid tumors, often in combination with other antitumor agents. Bevacizumab inhibits angiogenesis by binding to and neutralizing VEGF-A, thereby preventing tumor blood vessel formation. This combination is being evaluated in Phase 2 trials for efficacy and safety in advanced solid malignancies[1][3][5][7].
- Other names
- bevacizumab
02
Targets
TOP1 (DNA Topoisomerase I)PVRL4 (Nectin cell adhesion molecule 4)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SHR-A2102 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A2102 + bevacizumab.